Physician profile
Silvana Obici
NPI 1487730438
$1,525.54
in general payments reported to CMS, 2019-2025
12 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.49 · 2022: $123 · 2023: $444 · 2024: $621 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,261 · Education: $89.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.44 |
| Education | $89.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $463.26 | 2019-2024 | Wegovy |
| Abbott Laboratories | $337.68 | 2023-2024 | Freestyle Libre 3 |
| Medtronic, INC. | $275.42 | 2024-2025 | Signia, Minimed 780g, Sonicision |
| Insulet Corporation | $150.00 | 2025 | Omnipod |
| Dexcom, INC. | $123.07 | 2022 | |
| Tandem Diabetes Care, INC. | $30.94 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $29.92 | 2024 | Ilet Bionic Pancreas |
| Ascendis Pharma Endocrinology INC | $26.76 | 2025 | Yorvipath |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Recordati_rare_diseases_inc. | $22.53 | 2025 | Isturisa |
| Xeris Pharmaceuticals, INC. | $20.96 | 2024 | Gvoke Hypopen |
| Cequr Corporation | $20.00 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silvana Obici listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.